388 Queen St
Brisbane, QLD, Australia 4000
Tel: +1 (300) 974-621
14 articles about Microba
Microba Life Sciences Limited is pleased to announce that it has executed a commercial agreement with Sonic Healthcare Limited through a wholly owned subsidiary Douglass Hanly Moir Pathology Pty Ltd, to distribute Microba’s advanced infectious disease test MetaPanel™ in Australia.
Microba Life Sciences Limited announces that the first participants have been successfully dosed in the Phase I Clinical Trial of MAP 315, in Microba’s Therapeutic Program in Inflammatory Bowel Disease.
Mainz Biomed N.V. announced a research collaboration with Microba Life Sciences, a precision microbiome company leveraging a world-leading technology platform for measuring the human gut microbiome to discover and develop novel therapeutics for major diseases.
Microba Life Sciences Limited, a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™.
Sonic Healthcare Acquires Strategic Stake in Microba Life Sciences, Establishes Significant Commercial Partnership
Microba Life Sciences Limited is pleased to announce that leading medical diagnostics provider Sonic Healthcare Limited has agreed to invest $17.8m to acquire a 19.99% shareholding in Microba.
Microba Life Sciences Limited is excited to announce it has identified three therapeutic leads for the Company’s Immuno-Oncology program significantly earlier than expected.
Microba Life Sciences, a precision microbiome science company, will showcase its Therapeutic Platform and Discovery Platform for the identification of novel microbial signatures at annual Europe summit.
Results published in Cell, led by Mater Research and The University of Queensland, show that dietary restriction drives microbiome diversity changes in autistic individuals.
Precision microbiome science company, Microba Life Sciences, has appointed three respected key opinion leaders in Inflammatory Bowel Disease (IBD) to their IBD Advisory Panel to translate research into clinical outcomes for IBD sufferers.
Leaders in precision gut microbiome science Microba Life Sciences has united with Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies to advance understanding of the human gut microbiome in human health and disease.
Leaders in precision gut microbiome science, Microba Life Sciences have demonstrated how their proprietary Microba Community Profiler compares to other metagenomic profilers, with the study published in Frontiers in Microbiology.
Microba Life Sciences has appointed international executive, Mark Capone, as a Non-Executive Director of the Board, bringing with him more than 35 years of experience in the life sciences sector.
The Centre for Disease Control and Prevention has declared insufficient sleep a 'public health problem', with more than one-third of American adults not getting enough sleep on a regular basis.
Co-founder of Brisbane-based gut analysis company Microba, Professor Phil Hugenholtz, has been announced as the next Vice President of the International Society for Microbial Ecology (ISME).